Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UPGRADE

Financiado

Cerrado

Unlocking Precision Gene Therapy

Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene therapy products have reached the market and many more are entering clinical testing for s... ver más

30/06/2024

FONDAZIONE TELETHO...

15M€

Presupuesto del proyecto: 15M€

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-06-30

SC1-BHC-09-2018: Innovation platforms for advanced t...

I+D

Cerrada hace 6 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

FONDAZIONE TELETHON ETS

4.95M€ | Lider

OSR

N.D. | Participante

NEXT GENERATION DIAGNOSTIC S...

N.D. | Participante

UNITN

1.33M€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2017-88784-R DESARROLLO DE NUEVAS TECNOLOGIAS PARA LA EDICION PRECISA Y E... 136K€ Cerrado

PID2020-117143RB-I00 NUEVAS HERRAMIENTAS QUIMICAS CONCEPTUALES PARA TERAPIA GENIC... 263K€ Cerrado

GT-SKIN Gene Therapy for Inherited Skin Adhesion Disorders 2M€ Cerrado

PDC2021-121192-I00 UNA NUEVA PLATAFORMA QUIMICA PARA TERAPIA GENICA A LA CARTA 144K€ Cerrado

iAds Intelligent design of adenovirus vectors (iAds) 3M€ Cerrado

SAF2012-39504 MECANISMOS DE ESTABILIZACION Y CONTROL DE LA EXPRESION GENIC... 94K€ Cerrado

Duración del proyecto: 66 meses Fecha Inicio: 2018-12-04
Fecha Fin: 2024-06-30

Líder del proyecto

FONDAZIONE TELETHON ETS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 15M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Gene therapy has recently shown remarkable potential to offer definitive treatments for otherwise incurable diseases. Currently, seven gene therapy products have reached the market and many more are entering clinical testing for selected indications. Moreover, emerging technologies for targeted gene editing are complementing the scope of conventional gene transfer, opening the way to precise gene correction and making possible to silence, activate or recode any sequence of interest in the genome. However, in order to realize the full potential of these strategies and broaden application of gene therapy, the field has to solve several major hurdles, including: risk of insertional mutagenesis by gene transfer vectors, limited efficiency and durability of some gene correction strategies, off target effects of editing tools, poor tissue targeting and immune response to editing components and delivery vehicles. UPGRADE will offer radical new solutions to overcome these hurdles. We will exploit and further develop disruptive new technologies for precision gene and epigenome editing and for site-specific transgene insertion, and stringently characterize their specificity and cellular responses. We will combine these improved technologies with advanced viral and non-viral vectors enabling cell/tissue targeting and immune evasion, to generate prototypes of advanced medicinal products (AMP). The safety and efficacy profile of each AMP will be stringently validated in tissues (hematopoiesis, heart and skeletal muscle, liver, retina) and disease models (muscle wasting, storage and blood disorders, hypercholesterolemia) paradigmatic for unmet medical need and potential long-term cure, if the limitations of current gene therapy strategies are overcome. These AMPs represent versatile products portable to the treatment of several other diseases because of related pathogenesis or correction strategies, thus providing the basis for tackling diseases affecting large patient groups.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores